Known targets — ChEMBL curated mechanism
POLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PRIM1PRIM2RRM1RRM2RRM2B
The experimentally established mechanism targets of Clofarabine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE2A | O00408 | 8/20 | 1.00 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 1.00 |
| ▸ | PDE4D | Q08499 | 2/20 | 1.00 |
| ▸ | PDE3A | Q14432 | 2/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 1/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | NT5E | P21589 | 8/20 | 0.69 |
| ▸ | CD99 | P14209 | 2/20 | 0.69 |
| ▸ | LMNA | P02545 | 3/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
| ▸ | TP53 | P04637 | 2/20 | 0.64 |
| ▸ | PNP | P00491 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Clofarabine SCHEMBL12595105 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL17752021 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL1467619 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL5975001 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL12139443 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL23620882 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL15468200 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL9040 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL10026375 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A | |
| Clofarabine SCHEMBL18739936 | 1.00 | PDE2A (1.00) | PDE2AADORA3PDE4DPDE3AADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120107175-A1 | MODULAR RADIOCHEMISTRY SYNTHESIS SYSTEM | THE REGENTS OF THE UNIVERISTY OF CALIFORNIA (US) | 2012-05-03 | — | — | US | disclosed |
| US-8101740-B2 | Positron emission tomography probes for imaging immune activation and selected cancers | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2012-01-24 | — | — | US | disclosed |
| US-20090105184-A1 | POSITRON EMISSION TOMOGRAPHY PROBES FOR IMAGING IMMUNE ACTIVATION AND SELECTED CANCERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2009-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105184-A1 | POSITRON EMISSION TOMOGRAPHY PROBES FOR IMAGING IMMUNE ACTIVATION AND SELECTED CANCERS | PAICS, ADA, DCTD | PDE2A 1565/4885ADORA3 145/4885PDE4D 422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.